The first portable bionic hand restores the sense of touch in people who lost their limbs. Although the hand is still a prototype, we're one step closer to the day when a fully natural, sensorized prosthesis will be available.
Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped. The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.
Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
The Montreal-based startup ODS Medical is developing a handheld surgical guidance tool to improve accuracy in cancer surgery. Based on a set of advanced optical techniques, such as Raman spectroscopy, intrinsic fluorescence and diffuse reflectance spectroscopy, together with sophisticated machine learning algorithms, their laser technology measure scattered light to provide more specific information about the molecular makeup of the targeted brain tissue.
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study
LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.